Two Sigma Investments’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Two Sigma Investments's FDMT Position: Q3 2026 in Review
Two Sigma Investments increased its 4D Molecular Therapeutics (FDMT) stake by 34% in Q3 2026, buying an estimated $312K and bringing the position to 93,432 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3378.
Two Sigma Investments first reported a position in FDMT in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.45M in Q1 2023. 167 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Two Sigma Investments held 93,432 shares of 4D Molecular Therapeutics worth $1.34M as of Q3 2026.
- Two Sigma Investments bought 23,951 4D Molecular Therapeutics shares in Q3 2026, an estimated $312K.
- 4D Molecular Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q3 2026, its #3378 holding.
- Two Sigma Investments first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 19 quarters since.
- Two Sigma Investments's 4D Molecular Therapeutics position peaked at $3.45M in Q1 2023.
- 167 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Two Sigma Investments's 13F filing for Q3 2026, filed 16 Nov 2026.